Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07297693
PHASE1

A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers

Sponsor: Hanmi Pharmaceutical Company Limited

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HIP2503 and HCP1306 in healthy volunteers.

Official title: An Open-label, Randomized, Single-dose, Oral Administration, 2-sequence, 2-period, Crossover Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Subjects

Key Details

Gender

All

Age Range

19 Years - 64 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2025-12-19

Completion Date

2026-04-10

Last Updated

2025-12-22

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

HIP2503

Take 1 orally disintegrating tablet once per period

DRUG

HCP1306

Take 1 tablet once per period

Locations (1)

H plus Yangji Hospital

Seoul, Gwanak-gu, South Korea